WallStreetZenWallStreetZen

NASDAQ: CDT
Conduit Pharmaceuticals Inc Earnings & Revenue

CDT earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$535.0k
Current Profit Margin
0%

CDT Return on Equity

Insufficient data to display

Be the first to know when CDT announces earnings.

CDT Return on Assets

Current Company
-11.1%
Current Industry
2.9%
CDT is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CDT Return on Capital Employed

Current Company
-5.97%
Current Industry
19.5%

CDT vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CDT$0.00-$324.00k-$535.00kN/AN/A
ADAP$60.28M-$102.70M-$113.87M+0.26%N/A
GTHX$82.51M-$34.30M-$47.97M+93.68%N/A
QURE$15.84M-$253.10M-$308.48M+7.02%N/A
CHRS$257.24M-$191.46M-$237.89M-7.81%N/A

Conduit Pharmaceuticals Earnings & Revenue FAQ

What were CDT's earnings last quarter?

Conduit Pharmaceuticals (NASDAQ: CDT) reported Q4 2023 earnings per share (EPS) of $0.03, up 142.86% year over year. Total Conduit Pharmaceuticals earnings for the quarter were $1.78 million. In the same quarter last year, Conduit Pharmaceuticals's earnings per share (EPS) was -$0.07.

If you're new to stock investing, here's how to buy Conduit Pharmaceuticals stock.

What was CDT's earnings growth in the past year?

As of Q2 2024, Conduit Pharmaceuticals's earnings has grown year over year. Conduit Pharmaceuticals's earnings in the past year totalled -$535.00 thousand.

What was CDT's revenue last quarter?

Conduit Pharmaceuticals (NASDAQ: CDT) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Conduit Pharmaceuticals's revenue was $0.00.

What was CDT's revenue growth in the past year?

As of Q2 2024, Conduit Pharmaceuticals's revenue has grown null year over year. Conduit Pharmaceuticals's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.